AUA 2023 Bladder Cancer - Results from #20

Viewing 21-37 of 37 articles

AUA 2023: Neoadjuvant Immunotherapy for Muscle-Invasive Bladder Cancer

AUA 2023: Agent Orange Exposure and Risk of Bladder Cancer: A Nationwide Cohort Study

AUA 2023: The Immune-Related Adverse Events Paradox in Locally Advanced or Metastatic Urothelial Cancer Patients Receiving Atezolizumab: Analysis of Individual Participant Data From IMvigor210 and IMvigor211

AUA 2023: The Tolerability and Efficacy of BCG Administration after Recurrence in Bladder-Preserving Therapy For Muscle-invasive Bladder Cancer

AUA 2023: Avelumab First-line (1L) Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes From JAVELIN Bladder 100 in Subgroups Defined by Response to 1L Chemotherapy

AUA 2023: The Use of 68Ga-FAP-2286 PET Imaging in Patients with Localized Bladder Cancer

AUA 2023: Understanding the Impact of the Social Construct of Race on Receipt of Radical Cystectomy in the Largest Equal Access Health System in the US: The Veterans Affairs Health System

AUA 2023: Bladder Sparing Treatment in Patients with BCG Unresponsive Non-Muscle Invasive Bladder Cancer: An Analysis of Long-Term Survival Outcomes

AUA 2023: Transurethral En Bloc Resection versus Standard Resection of Bladder Tumor: A Multi-Center Randomized Trial (EB-StaR Study)

AUA 2023: CORE1: Phase 2 Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin (BCG)

AUA 2023: Can Experience of Blue Light Cystoscopy Improve a Surgeon's White Light Resection? Data from the PHOTO Trial

AUA 2023: A Transformer-Augmented Deep Learning Algorithm, CystoNet-T, for Improved Cystoscopic Bladder Cancer Detection

AUA 2023: Deep Learning Algorithms for Multi-Region Bladder Cancer Segmentation

AUA 2023: Sequential Intravesical Gemcitabine and Docetaxel for Treatment-Naive and Previously Treated Intermediate-Risk Non-Muscle Invasive Bladder Cancer

AUA 2023: The Role of Flexible Blue Light Cystoscopy in Surveillance of Non-muscle Invasive Bladder Cancer. Results From a Nordic Registry

AUA 2023: Progression-Free Survival as Surrogate Endpoint in High-Risk Non-Muscle Invasive Bladder Cancer Studies: Results from a Machine Learning-Based Analysis of a Large Multi-Institutional Database

AUA 2023: Comparison of Intravesical Therapy and Surgery as Treatment Options for Recurrent Bladder Cancer (CISTO): Collection of Patient-Reported Outcomes

1
2